Advertisement

ADVERTISEMENT

Jessica Garlewicz, Associate Digital Editor

Conference Highlights
Dermatology Week 2022: Revolutionary Updates and Insights for Today’s Providers
06/09/2022
Jessica Garlewicz, Associate Digital Editor
This year’s spring Dermatology Week continued its focus on providing dermatology education for today’s providers in a virtual setting.
This year’s spring Dermatology Week continued its focus on providing dermatology education for today’s providers in a virtual setting.
This year’s spring Dermatology...
06/09/2022
The Dermatologist
Ginette A. Okoye, MD
Conference Coverage
Epidemiology and Health Disparities in Hidradenitis Suppurativa
05/14/2022
Jessica Garlewicz, Associate Digital Editor
During her session presented at Dermatology Week 2022, Ginette A. Okoye, MD, FAAD, highlighted the epidemiology and health disparities surrounding hidradenitis suppurativa.
During her session presented at Dermatology Week 2022, Ginette A. Okoye, MD, FAAD, highlighted the epidemiology and health disparities surrounding hidradenitis suppurativa.
During her session presented at...
05/14/2022
The Dermatologist
Peter Lio, MD, FAAD
Conference Coverage
IL-13 Inhibitors for Atopic Dermatitis
05/13/2022
Jessica Garlewicz, Associate Digital Editor
During his session presented at Dermatology Week 2022, Peter Lio, MD, FAAD, presented new and upcoming IL-13 inhibitors for treating atopic dermatitis by sharing their mechanisms of action and clinical data.
During his session presented at Dermatology Week 2022, Peter Lio, MD, FAAD, presented new and upcoming IL-13 inhibitors for treating atopic dermatitis by sharing their mechanisms of action and clinical data.
During his session presented at...
05/13/2022
The Dermatologist
NPF Endorsed Features
Updates and Insights on Risankizumab for Psoriatic Disease
05/12/2022
Jessica Garlewicz, Associate Digital Editor
Risankizumab-rzaa is the only IL-23 inhibitor approved for adults with moderate to severe plaque psoriasis and active psoriatic arthritis.
Risankizumab-rzaa is the only IL-23 inhibitor approved for adults with moderate to severe plaque psoriasis and active psoriatic arthritis.
Risankizumab-rzaa is the only...
05/12/2022
The Dermatologist
Brett King, MD, PhD
Conference Coverage
The Pathogenesis and Treatment of Alopecia Areata
05/12/2022
Jessica Garlewicz, Associate Digital Editor
During his session presented at Dermatology Week 2022, Brett King, MD, PhD, discussed the lack of effective treatment for alopecia areata, and recent data on utilizing JAK inhibitors.
During his session presented at Dermatology Week 2022, Brett King, MD, PhD, discussed the lack of effective treatment for alopecia areata, and recent data on utilizing JAK inhibitors.
During his session presented at...
05/12/2022
The Dermatologist
Victoria Werth, MD
Conference Coverage
Treating and Evaluating Cutaneous Lupus Erythematosus
05/12/2022
Jessica Garlewicz, Associate Digital Editor
During her session presented at Dermatology Week 2022, Victoria Werth, MD, went over the evaluation and treatment of cutaneous lupus erythematosus.
During her session presented at Dermatology Week 2022, Victoria Werth, MD, went over the evaluation and treatment of cutaneous lupus erythematosus.
During her session presented at...
05/12/2022
The Dermatologist
Brian Kim, MD, MTR, FAAD
Conference Coverage
Experts Insights into Itch
05/11/2022
Jessica Garlewicz, Associate Digital Editor
During Dermatology Week 2022, Shawn Kwatra, MD, and Brian Kim, MD, MTR, FAAD, hosted a discussion-based session to offer insights on the pathophysiology of itch.
During Dermatology Week 2022, Shawn Kwatra, MD, and Brian Kim, MD, MTR, FAAD, hosted a discussion-based session to offer insights on the pathophysiology of itch.
During Dermatology Week 2022,...
05/11/2022
The Dermatologist
Joel Gelfand, MD, MSCE
Conference Coverage
Derm Week Review: Managing Moderate to Severe Psoriasis: Interleukin Inhibitors
05/11/2022
Jessica Garlewicz, Associate Digital Editor
In his session presented at Dermatology Week 2022, Joel Gelfand, MD, MSCE, discussed the current treatment landscape for psoriasis using recent data on IL-12, IL-23, and IL-17 inhibitors.
In his session presented at Dermatology Week 2022, Joel Gelfand, MD, MSCE, discussed the current treatment landscape for psoriasis using recent data on IL-12, IL-23, and IL-17 inhibitors.
In his session presented at...
05/11/2022
The Dermatologist
Brittany Craiglow, MD
Conference Coverage
Insights on Pediatric Dermatology: Atopic Dermatitis and Needles
05/11/2022
Jessica Garlewicz, Associate Digital Editor
During her session presented at Dermatology Week 2022, Brittany Craiglow, MD, shared the evolving treatment options in pediatric dermatology.
During her session presented at Dermatology Week 2022, Brittany Craiglow, MD, shared the evolving treatment options in pediatric dermatology.
During her session presented at...
05/11/2022
The Dermatologist
Dermatology Week details
Conference Coverage
Expert Insights: Impactful Lectures and More at Dermatology Week 2022
05/10/2022
Jessica Garlewicz, Associate Digital Editor
Dermatology Week returns May 11-14, 2022, after a successful inaugural year.
Dermatology Week returns May 11-14, 2022, after a successful inaugural year.
Dermatology Week returns May...
05/10/2022
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use